SYNTHETIC GLYCOCONJUGATE VACCINE PROTOTYPE AGAINST STREPTOCOCCUS SUIS

The invention provides for a vaccine against S. suis serotype 2. The vaccine comprises chemically synthesized fragments and thus may be made widely commercially available. The vaccine is used in the livestock production and may be adapted for use against other serotypes of S. suis such as serotypes 1, 1/2, 3, 9, and 14. Also, the vaccine may be adapted for use in humans..

Medienart:

Patent

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Europäisches Patentamt - (2023) vom: 04. Mai Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Beteiligte Personen:

SEGURA MARIELA [VerfasserIn]
GOTTSCHALK MARCELO [VerfasserIn]
LOWARY TODD [VerfasserIn]
LI PEI-JHEN [VerfasserIn]
JANA MANAS [VerfasserIn]
LO FIEGO MARCOS [VerfasserIn]
SWEENEY RYAN [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
C07H: Sugars; derivatives thereof; nucleosides; nucleotid (...)
C08B: Polysaccharides; derivatives thereof (polysaccharid (...)
cet
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2023-05-04, Last update posted on www.tib.eu: 2023-08-16, Last updated: 2023-08-18

Patentnummer:

WO2023070223

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA017249902